Figure S2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors

相似书籍

• Figure 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
  由: John Powderly (15026168)
  出版: (2025)
• Figure 2 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
  由: John Powderly (15026168)
  出版: (2025)
• Figure 3 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
  由: John Powderly (15026168)
  出版: (2025)
• Figure S1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
  由: John Powderly (15026168)
  出版: (2025)
• Table 1 from IPH5201, an Anti-CD39 mAb, as Monotherapy or in Combination with Durvalumab in Advanced Solid Tumors
  由: John Powderly (15026168)
  出版: (2025)